Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

Core Insights - Revolution Medicines, Inc. has initiated dosing in the RASolve 301 Phase 3 clinical trial, evaluating daraxonrasib (RMC-6236) for RAS mutant non-small cell lung cancer (NSCLC) [1][3] - The trial aims to enroll approximately 420 patients with previously treated locally advanced or metastatic NSCLC, focusing on those with specific RAS mutations [2][4] - Daraxonrasib is a multi-selective inhibitor targeting RAS mutations, which are present in about 30% of NSCLC cases, and is expected to provide a new therapeutic option where current treatments are limited [4][5] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [6][7] - The company's pipeline includes multiple RAS(ON) inhibitors, with daraxonrasib being a key candidate currently in clinical trials [7] Industry Context - NSCLC is a leading cause of cancer-related mortality, with over 197,000 diagnoses annually in the U.S. [4] - RAS mutations are significant oncogenic drivers in NSCLC, complicating treatment due to the genetic diversity of the disease [4]